RESUMEN
We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Here we report using various p53 mutants that two separate domains of p53 protein affect p53 binding to platinated DNA. Mutations within the central core of p53, the domain responsible for sequence-specific DNA binding activity, completely eliminated p53 binding to platinated DNA. Based on competition experiments p53 preferred binding to sequence-specific DNA molecules over platinated DNA molecules. However, p53 binding to platinated DNA molecules was significantly stronger than p53 interactions with DNA molecules lacking damage and a p53 consensus site. Finally, an antibody specific to the C-terminal domain of p53 (pAb421) which activates sequence-specific DNA binding activity inhibited p53 binding to platinated DNA. Taken together, these results suggest that in addition to binding to p53 DNA binding sites, p53 also interacts with cisplatin-damaged DNA molecules.
Asunto(s)
Cisplatino/toxicidad , Daño del ADN , ADN/efectos de los fármacos , ADN/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Secuencia de Bases , Sitios de Unión , Secuencia de Consenso , ADN/genética , ADN de Neoplasias/efectos de los fármacos , ADN de Neoplasias/genética , ADN de Neoplasias/metabolismo , Genes p53 , Humanos , Datos de Secuencia Molecular , Unión Proteica , Células Tumorales CultivadasRESUMEN
In this study the transactivation potential and DNA binding activities of p53 protein were examined following exposure of A2780 cells, a human ovarian carcinoma cell line, to the DNA damaging agent, cis-diamminedichloroplatinum II (cisplatin). The endogenous murine double minute-2 gene (mdm-2) was used to monitor the ability of p53 to transactivate genes. Northern analysis showed an induction of mdm-2 mRNA upon cisplatin treatment. It was further demonstrated, using an RNase protection assay, that the p53-responsive, mdm-2 promoter (P2) was activated in cisplatin-treated A2780 cells. However, when p53 protein DNA binding activity was analyzed, there was no detectable increase in p53 sequence-specific DNA binding activity during the period of time following DNA damage when mdm-2 mRNA was induced. Instead the increase in p53 protein observed in nuclear, cytoplasmic, and whole cell extracts correlated with a latent conformation of p53 that lacked sequence-specific DNA binding activity. At low doses of cisplatin, these latent pools of p53 increased in parallel with mdm-2 gene activation and were detectable as early as 4 h following cisplatin treatment. In vitro attempts to convert the latent p53 into an active, sequence-specific DNA binding conformation were unsuccessful. Even though cisplatin-induced p53 lacked sequence-specific DNA binding activity, it does possess an increased affinity for cisplatin-damaged duplex DNA molecules. This represents the first identification where cisplatin treatment induces a p53 protein, lacking sequence-specific DNA binding but with an increased affinity for platinated DNA molecules.